Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 7;12:9341–9350. doi: 10.2147/OTT.S221040

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Tang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Antitumor activity of HELA/CART cells in a xenograft model in vivo. (A) BALB/c nude mice were inoculated with SUNE1-LMP1 cells overexpressing LMP1 and allowed to develop established tumors over 10 days. The results are expressed as the mean tumor volume (mm³) (mean±SD) for the six groups (N=6/group). The HELA/137CART group was able to inhibit tumor growth more effectively than the HELA/CART and HELA/134CART groups. *p<0.05; **p<0.01. (B) Images of representative tumor samples from sacrificed mice are shown. (C) The tumor samples were paraffin-embedded and stained with H&E. The tumor tissue necrosis area of the HELA/CART, HELA/134CART, and HELA/137CART treatment groups was larger and showed more lymphocyte infiltration, compared with control groups. (D) Immunohistochemical (IHC) staining for anti-human CD3ζ was performed on tumor samples. HELA/134CART and HELA/137CART cells were more likely to infiltrate into tumors than HELA/CART cells. (E) The percent of human CD3ζ-positive cells in tumor tissue. The ratios of HELA/134CART and HELA/137CART groups are high than HELA/CART group. ns, no significant difference; ***p<0.001.